Novel Compositions for Treating or Preventing Dermal Disorders

• Status: Completed
• Trial end date: 2017-11-30
• Target enrollment: 0
• Participant gender: All

Summary

This trial examines the impact of a topical formulation of rapamycin on dermal thickness and senescence.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Drexel University
• Treatments: Everolimus; Sirolimus

Criteria

Inclusion Criteria:

• Healthy adults

Exclusion Criteria:

• Individuals with any chronic disease will be excluded from the study including those with the following conditions:

• Diabetes

• Any type of Malignancy

• Severe coronary artery disease

• HIV infection

• Hepatitis C or B

• Any sign of skin disorder or disease aside from normal aging, dermal atrophy, or seborrheic keratoses.

• Premenopausal women will be excluded

• Patients taking the following medications will be excluded:

• Cyclosporin

• Calcium channel blockers: diltiazem, verapamil

• Antifungal agents e.g. clotrimazole, fluconazole, itraconazole

• Antibiotics: clarithromycin, erythromycin, rifampicin

• Anticonvulsants: carbamazepine, phenobarbitone, phenytoin

• Antinausea drugs e.g. metoclopramide

• Other drugs e.g. danazol, protease inhibitors (e.g. for HIV and hepatitis C including ritonavir, indinavir, boceprevir, and telaprevir)

• Grapefruit juice

• St John's wort (Hypericum perforatum, hypericin)